亚太地区传染病治疗市场预测至 2030 年 - 区域分析 - 按药物类别(抗病毒、抗菌、抗真菌等)、适应症(艾滋病毒、肝炎、结核病、流感、HPV 等)、给药途径(口服、肠胃外、外用等)和分销渠道(医院药房、零售药房等)

Historic Data: 2020-2021   |   Base Year: 2022   |   Forecast Period: 2023-2030


No. of Pages: 101    |    Report Code: BMIRE00030366    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
Asia Pacific Infectious Disease Therapeutics Market
2022 年亚太地区传染病治疗市场价值为 259.0461 亿美元,预计到 2030 年将达到 374.1507 亿美元;预计 2022 年至 2030 年的复合年增长率为 4.7%。

发展中国家日益增长的机会推动亚太地区传染病治疗市场发展

预计传染病发病率的不断上升将增加发展中国家传染病治疗药物的销量。由于数据要求较少且监管严格,亚太地区已成为一个适应性强且商业友好的中心。此外,新兴国家对健康研究和生命科学的高额投资在推动发展中国家最新技术方面发挥着关键作用,而这反过来又支持了人们对传染病诊断和治疗的倾向。例如,联合国艾滋病规划署呼吁到 2025 年投资 290 亿美元,以满足中低收入国家在艾滋病应对方面的需求。因此,印度和韩国新兴传染病治疗市场中的关键传染病治疗产品制造商预计将在未来看到丰厚的机遇。这是由于这些国家肝炎、HAI、HIV 和流感等传染病的发病率高;患者人数众多;人口可支配收入增加;医疗保健基础设施改善;以及医疗旅游业不断增长。

亚太传染病治疗市场概览

亚太传染病治疗市场细分为中国、印度、日本、韩国、澳大利亚和亚太其他地区。预计亚太地区在预测期内的复合年增长率最快。由于全球医疗保健支出增加、慢性病和传染病发病率上升以及老年人口基数不断增长,该地区的市场预计将增长。在中国,流感、乙肝、感染性腹泻等传染病很常见;在印度,伤寒、疟疾、黄疸、肺结核和艾滋病很常见。流感、乙肝和感染性腹泻是中国三大常见传染病。据《公共卫生前沿》报道,2021年冬季流感高峰与新冠肺炎疫情在该国暴发的时间相吻合。世界银行中国局局长2020年表示,由于人口不断增长、野生动物数量众多、栖息地破碎化和畜牧业生产水平高,中国面临较高的传染病风险。考虑到中国传染病发病率不断上升,世界银行执行董事会批准为新发传染病预防、准备和应对项目提供3亿美元贷款。这将有助于中国降低人畜共患疾病和其他新发健康威胁的风险。因此,传染病发病率的上升和为控制这些疾病而采取的措施预计将在未来几年推动中国传染病治疗市场的发展。

亚太传染病治疗市场收入及预测至 2030 年(百万美元)

亚太传染病治疗市场细分

亚太传染病治疗市场分为药物类别、适应症、给药途径、分销渠道和国家。

根据药物类别,亚太传染病治疗市场分为抗病毒、抗菌、抗真菌和其他。抗病毒部分在 2022 年占据了最大的市场份额。

就适应症而言,亚太传染病治疗市场分为艾滋病毒、肝炎、结核病、流感、HPV 和其他。 2022 年,艾滋病毒占据了最大的市场份额。

根据给药途径,亚太传染病治疗市场细分为口服、肠外、外用和其他。口服部分在 2022 年占据了最大的市场份额。

在分销渠道方面,亚太传染病治疗市场细分为医院药房、零售药房和其他。2022 年,医院药房占据了最大的市场份额。

按国家/地区划分,亚太传染病治疗市场细分为中国、日本、印度、澳大利亚、韩国和亚太地区其他地区。 2022 年,中国占据了亚太地区传染病治疗市场的主导份额。

AbbVie Inc、Astellas Pharma Inc、Bayer AG、F. Hoffmann-La Roche Ltd、Gilead Sciences Inc、GSK Plc、Merck & Co Inc、Pfizer Inc 和 Shionogi & Co Ltd 是亚太地区传染病治疗市场的一些领先公司。

Asia Pacific Infectious Disease Therapeutics Strategic Insights

Strategic insights for Asia Pacific Infectious Disease Therapeutics involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/asia-pacific-infectious-disease-therapeutics-market-strategic-framework.webp
Get more information on this report

Asia Pacific Infectious Disease Therapeutics Report Scope

Report Attribute Details
Market size in 2022 US$ 25,904.61 Million
Market Size by 2030 US$ 37,415.07 Million
Global CAGR (2022 - 2030) 4.7%
Historical Data 2020-2021
Forecast period 2023-2030
Segments Covered By 药物类别
  • 抗病毒
  • 抗菌
  • 抗真菌
By 适应症
  • 艾滋病毒
  • 肝炎
  • 肺结核
  • 流感
  • HPV
By 分销渠道
  • 医院药房
  • 零售药房
Regions and Countries Covered 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 亚太其他地区
Market leaders and key company profiles
  • AbbVie Inc
  • Astellas Pharma Inc
  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • GSK Plc
  • Merck & Co Inc
  • Pfizer Inc
  • Shionogi & Co Ltd
  • Get more information on this report

    Asia Pacific Infectious Disease Therapeutics Regional Insights

    The regional scope of Asia Pacific Infectious Disease Therapeutics refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/asia-pacific-infectious-disease-therapeutics-market-geography.webp
    Get more information on this report

    The List of Companies - Asia Pacific Infectious Disease Therapeutics Market

    1. AbbVie Inc
    2. Astellas Pharma Inc
    3. Bayer AG
    4. F. Hoffmann-La Roche Ltd
    5. Gilead Sciences Inc
    6. GSK Plc 
    7. Merck & Co Inc
    8. Pfizer Inc
    9. Shionogi & Co Ltd

    Frequently Asked Questions
    How big is the Asia Pacific Infectious Disease Therapeutics Market?

    The Asia Pacific Infectious Disease Therapeutics Market is valued at US$ 25,904.61 Million in 2022, it is projected to reach US$ 37,415.07 Million by 2030.

    What is the CAGR for Asia Pacific Infectious Disease Therapeutics Market by (2022 - 2030)?

    As per our report Asia Pacific Infectious Disease Therapeutics Market, the market size is valued at US$ 25,904.61 Million in 2022, projecting it to reach US$ 37,415.07 Million by 2030. This translates to a CAGR of approximately 4.7% during the forecast period.

    What segments are covered in this report?

    The Asia Pacific Infectious Disease Therapeutics Market report typically cover these key segments-

  • 药物类别 (抗病毒, 抗菌, 抗真菌)
  • 适应症 (艾滋病毒, 肝炎, 肺结核, 流感, HPV)
  • 分销渠道 (医院药房, 零售药房)
  • What is the historic period, base year, and forecast period taken for Asia Pacific Infectious Disease Therapeutics Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Infectious Disease Therapeutics Market report:

  • Historic Period : 2020-2021
  • Base Year : 2022
  • Forecast Period : 2023-2030
  • Who are the major players in Asia Pacific Infectious Disease Therapeutics Market?

    The Asia Pacific Infectious Disease Therapeutics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • AbbVie Inc
  • Astellas Pharma Inc
  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • GSK Plc
  • Merck & Co Inc
  • Pfizer Inc
  • Shionogi & Co Ltd
  • Who should buy this report?

    The Asia Pacific Infectious Disease Therapeutics Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Asia Pacific Infectious Disease Therapeutics Market value chain can benefit from the information contained in a comprehensive market report.